The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-07-25 and is reviewed periodically as new material appears.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
=== Efficacy === The vaccine efficacy of a COVID-19 vaccine or any other vaccine is evaluated in controlled clinical trials. It is an estimate of how many people who received the vaccine got the disease compared to how many people who got a placebo had the same outcome. On 2 February 2021, an interim analysis from the Moscow trial was published in The Lancet reporting an efficacy of 91.6% (95% CI, 85.6–95.2%) after the second dose for all age groups, with no unusual side effects. For the age group of 60 years and older, the reported efficacy was 91.8%. On 12 May, a group of biostatisticians from Russia, the US, France, Italy and the Netherlands questioned the efficacy results in a correspondence in The Lancet, highlighting data discrepancies, substandard reporting, apparent errors and numerical inconsistencies and an implausible homogeneity in vaccine efficacy across age groups. The authors responded by saying that they had provided the regulatory authorities with all the data necessary for obtaining approval, and that the data included with the paper were enough for readers to confirm the reported vaccine efficacy. They also addressed the protocol queries, and said numerical inconsistencies were "simple typing errors that were formally corrected". In June 2022 a group of biostatisticians from Australia and Singapore published a paper suggesting that the almost identical efficacy for every age group from the Lancet paper is highly unlikely to occur in genuine experimental data.
=== Procedures === Section 316 of the Criminal Procedure Code states that the death penalty in Singapore is to be conducted by hanging. Judicial hangings always take place shortly before dawn on a Friday and are conducted by the long drop method. The Singapore government has affirmed its choice of execution by hanging in favour of other methods. It is a normal practice for everyone present in the courtroom to stand and remain silent before the death sentence is passed. The judge will then proceed to announce the death sentence on the accused, who has been found guilty and convicted of the capital offence. The condemned will be given notice at least four days before execution. In the case of foreigners sentenced to death, their families and diplomatic missions or embassies will be given one to two weeks' notice.
Adrenomedullin (AM) Angiopoietin (Ang) Autocrine motility factor Bone morphogenetic proteins (BMPs) Ciliary neurotrophic factor family Colony-stimulating factors Epidermal growth factor (EGF) Ephrin Fibroblast growth factor (FGF) Foetal Bovine Somatotrophin (FBS) GDNF family of ligands Growth differentiation factor-9 (GDF9) Hepatocyte growth factor (HGF) Hepatoma-derived growth factor (HDGF) Insulin Insulin-like growth factors Interleukins Keratinocyte growth factor (KGF) Migration-stimulating factor (MSF) Macrophage-stimulating protein (MSP), also known as hepatocyte growth factor-like protein (HGFLP) Myostatin (GDF-8) Neuregulins Neurotrophins Placental growth factor (PGF) Platelet-derived growth factor (PDGF) Transforming growth factors Vascular endothelial growth factor (VEGF)
=== General === The croaking gourami is a fairly shy, peaceful fish that does well in most community aquaria, not causing problems with tankmates. Males can be fairly territorial and aggressive towards each other during breeding periods, but will not cause harm and can peacefully coexist given a large enough aquarium. This species requires a tank no smaller than 40 L (11 U.S. gal), preferably larger. The croaking gourami will prowl about all areas of the aquarium, preferring to lurk among reeds and under large leaves close to the water surface. At night, they might be found "sleeping" at the bottom, even resting on the substrate (which is not normally a cause for concern), or hovering motionless at the water surface. Like all members of the suborder Anabantoidei, if necessary, the croaking gourami can breathe atmospheric oxygen from above the water surface using a specialized labyrinth organ. It is important, therefore, that the surface of the water be exposed to fresh air, usually accomplished by keeping them in an open-top tank or using a hood that allows air ventilation. If the tank has good air pumps, this is not always needed, since the air pumps will refresh the air above the water. The aquarium should be heavily planted and have at least part of the surface shaded by broad leaves or floating plants, since the croaking gourami will become severely stressed in bare tanks without various hiding places. A darker substrate will make this fish feel comfortable and help show off its subtle colors.
== Etymology == Neanderthals are named after the Neander Valley in which the first identified specimen was found. The valley was spelled Neanderthal and the species was spelled Neanderthaler in German until the spelling reform of 1901. The spelling Neandertal for the species is occasionally seen in English, even in scientific publications, but the scientific name, H. neanderthalensis, is always spelled with th according to the principle of priority. The vernacular name of the species in German is always Neandertaler ("inhabitant of the Neander Valley"), whereas Neandertal always refers to the valley. The valley itself was named after the late 17th century German theologian and hymn writer Joachim Neander, who often visited the area. His grandfather, a musician, had changed the family name from the original German Neumann "new man" (cf. "Newman") to the Graeco-Roman form Neander (deriving with Greek ἀνήρ ănḗr "man"), following the fashion of the time. The th in Neanderthal can be pronounced as /t/ (hence ) following the German convention or Anglicized as fricative /θ/ (hence ), as per the standard English pronunciation of th. Neanderthal 1, the type specimen, was known as the "Neanderthal cranium" or "Neanderthal skull" in anthropological literature, and the individual reconstructed on the basis of the skull was occasionally called "the Neanderthal man". In 1863, Irish geologist William King extended the name "Neanderthal man" from the individual specimen to the entire species.
Sources: en.wikipedia.org
=== Indian philosophy === The Upanishads, principal scriptures of Hinduism, propound a creation theory wherein the supreme self transmutes itself to become the creation by exerting tremendous effort and strenuous labor (śrama), which is enabled on by tapas or "heat", considered as the most important element in the entire creation process. The word tapas, in Sanskrit literature, is understood as a reference to the sexual heat or warmth that incubates the birth of life. The root word tapas was commonly used for descriptions of sexual desire and love. The word kama (desire) was homologized with tapas (heat) to explain the emotions and energy that leads to intercourse. The connection between bodily heat (tapas) and sexual desire (kama) is not just metaphorical but is found to be rooted in physiology, "All adolescent and fertile adults are hot." The internal bodily heat, apart from being present inherently in certain body types (thinness more heat), is generated by processes such as "menstruation, childbirth, consumption of hot food, sexual desire" and certain emotions like anger and jealousy. While heat is regarded as necessary to sustain life, with complete coldness corresponding to death, excessive bodily heat is "undesirable and dangerous" as it causes the body to deteriorate by internal consumption. A state of "relative coolness" is considered ideal. Women, in general, are deemed as relatively hotter than men, partly due to menstruation and pregnancies, which result in higher concentrations of blood to the womb.
Additionally, when physicochemical properties or structures are expressed by numbers, one can find a mathematical relationship, or quantitative structure-activity relationship, between the two. The mathematical expression, if carefully validated, can then be used to predict the modeled response of other chemical structures. A QSAR has the form of a mathematical model:
== Applications and market == In 2014, the global market for aspartic acid was 39.3 thousand short tons (35.7 thousand tonnes) or about $117 million annually. The three largest market segments include the U.S., Western Europe, and China. Current applications include biodegradable polymers (polyaspartic acid), low calorie sweeteners (aspartame), scale and corrosion inhibitors, and resins.
=== An overview of the GT model === The model proposed by John A. Greenwood and John H. Tripp (GT), extended the GW model to contact between two rough surfaces. The GT model is widely used in the field of elastohydrodynamic analysis. The most frequently cited equations given by the GT model are for the asperity contact area
Sources: en.wikipedia.org
ketamine (K; Ketalar, Ketaset, Ketanest; "Ket", "Kit Kat", "Special-K", "Vitamin K", "Jet Fuel", "Horse Tranquilizer") methoxetamine (Mex, Mket, Mexi) phencyclidine (PCP; Sernyl; "Angel Dust", "Rocket Fuel", "Sherm", "Killer Weed", "Super Grass") nitrous oxide (N2O; "NOS", "Laughing Gas", "Whippets", "Balloons") Psychedelics Phenethylamines 2C-B ("Nexus", "Venus", "Eros", "Bees") 2C-E ("Eternity", "Hummingbird") 2C-I ("Infinity") 2C-T-2 ("Rosy") 2C-T-7 ("Blue Mystic", "Lucky 7") DOB DOC DOI DOM ("Serenity, Tranquility, and Peace" ("STP")) MDMA ("Ecstasy", "E", "Molly", "Mandy", "MD", "Crystal Love") mescaline (found in peyote and Trichocereus macrogonus (Peruvian torch, San Pedro cactus, Echinopsis langeniformis)) Tryptamines (including ergolines and lysergamides) 5-MeO-DiPT ("Foxy", "Foxy Methoxy") 5-MeO-DMT (found in various plants like chacruna, jurema, vilca, and yopo) α-methyltryptamine (αMT; Indopan; "Spirals") bufotenin (secreted by Bufo alvarius, also found in various Amanita mushrooms) dimethyltryptamine (DMT; "Dimitri", "Disneyland", "Spice"; found in large amounts in Psychotria and in D. cabrerana) lysergic acid amide (LSA; ergine; found in morning glory and Hawaiian baby woodrose seeds) lysergic acid diethylamide (LSD; L; Delysid; "Acid", "Sid".
== Honours == Du Vigneaud joined Alpha Chi Sigma while at the University of Illinois in 1930. He was elected to the United States National Academy of Sciences and the American Philosophical Society in 1944, and the American Academy of Arts and Sciences in 1948. He received the 1955 Nobel Prize in Chemistry "for his work on biochemically important sulphur compounds, especially for the first synthesis of a polypeptide hormone," a reference to his work on the peptide hormone oxytocin.
=== Monitoring === The Epidermolysis Bullosa Disease Activity and Scarring index (EBDASI) is a scoring system that objectively quantifies the severity of EB. The EBDASI is a tool for clinicians and patients to monitor the severity of the disease. It has also been designed to evaluate the response to new therapies for the treatment of EB. The EBDASI was developed and validated by Professor Dedee Murrell and her team of students and fellows at the St George Hospital, University of New South Wales, in Sydney, Australia. It was presented at the International Investigative Dermatology congress in Edinburgh in 2013 and a paper-based version was published in the Journal of the American Academy of Dermatology in 2014.
==== Glycosaminoglycans ==== Topical glycosaminoglycans supplements can help to provide temporary restoration of enzyme balance to slow or prevent matrix breakdown and consequent onset of wrinkle formation. Glycosaminoglycans (GAGs) are produced by the body to maintain structural integrity in tissues and to maintain fluid balance. Hyaluronic acid is a type of GAG that promotes collagen synthesis, repair, and hydration. GAGs serve as a natural moisturizer and lubricant between epidermal cells to inhibit the production of matrix metalloproteinases (MMPs).
== Additional facts == On Malacards, it has an information score of 7/100. There are currently no known genes or related disorders related to chondronectins. There are no current therapeutics, variations, expressions, pathways, GO terms or genetic tests for chondronectins currently. Chondronectin has been described as a trimeric glycoprotein with compact globular properties. The protein has most commonly been detected in cartilage related fluids such as synovial fluid and plasma. Chondronectin functions primarily as an attachment factor between chondrocytes and collagen based matrix materials. Most currently available information on chondronectin comes from isolation and characterization studies completed during the 1980s.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。